Table 1 Demographic, biochemical, and genetic characteristics of pediatric-onset (N = 31) and adult-onset (N = 203) cohorts
From: The impact of dysfunctional variants of ABCG2 on hyperuricemia and gout in pediatric-onset patients
Pediatric-onset (N = 31) | Adult-onset (N = 203) | Fisher’s test P value | |||
N | % | N | % | ||
Sex M/F | 26/5 | 83.9/16.1 | 174/29 | 85.7/14.3 | 0.786 |
Hyperuricemia/primary gout | 17/14 | 58.1/41.9 | 41/162 | 79.8/21.2 | < 0.0001 |
Familial occurrence | 23 | 74.2 | 64 | 31.5 | < 0.0001 |
Familial occurrence, | |||||
1st degree | 19 | 61.3 | Not specified | – | |
2nd degree | 4 | 12.9 | |||
No treatment | 15 | 48.4 | 36 | 17.7 | < 0.0001 |
Allopurinol treatment | 12 | 38.7 | 154 | 75.9 | |
Febuxostat treatment | 4 | 12.9 | 13 | 6.4 | |
rs2231142 | |||||
GG | 14 | 45.2 | 124 | 61.1 | 0.001 |
GT | 10 | 32.3 | 72 | 35.5 | |
TT | 7 | 22.6 | 7 | 3.4 | |
rs2231142, MAF | 24 | 38.7 | 86 | 21.2 | 0.005 |
rs2231137, MAF ** | 1 | 1.6 | 7 | 1.7 | 1.000 |
rs769734146, MAF | 1 | 1.6 | 1 | 0.2 | 0.623 |
rs750972998, MAF | 1 | 1.6 | 0 | 0.0 | 0.278 |
rs199854112, MAF | 1 | 1.6 | 0 | 0.0 | 0.278 |
Median (IQR) | Range | Median (IQR) | Range | Wilcoxon’s test P value | |
Age of onset, years | 15.0 (4.0) | 1–18 | 43.5 (24.2) | 18–84 | < 0.0001 |
Age now, years | 19.0 (19.5) | 3–59 | 55.0 (22.0) | 19–90 | < 0.0001 |
BMI now | 25.1 (7.6) | 16.0–41.0 | 29.0 (5.1) | 19.5–50.0 | < 0.0001 |
Max recorded SU, μmol/l (N = 34/155) # | 522.0 (144.0) | 314–796 | 481.0 (101.0) | 252–770 | 0.021 |
SU on treatment, μmol/l (N = 17/176) # | 419.0 (96.0) | 300–608 | 371.5 (132.5) | 252–770 | 0.091 |
FE-U on treatment (N = 15/173) # | 3.2 (1.7) | 1.6–5.5 | 3.2 (1.7) | 0.9–14.3 | 0.403 |
Treatment dose, mg * (N = 15/168) | 100 (200) | 80–500 | 200 (200) | 0–800 | 0.181 |